(1-Amino-2-methylpropan-2-yl) acetate | 741233-99-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1-Amino-2-methylpropan-2-yl) acetate
• CAS: 741233-99-8
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: KVRWIDXKTNZMES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1-Amino-2-methylpropan-2-yl) acetate 在 盐酸 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles

  摘要：

  The human T cell leukemia/lymphotropic virus type 1 (HTLV-I) is clinically associated with adult T cell leukemia/lymphoma, HTLV-I associated myelopathy/tropical spastic paraparesis, and a number of other chronic inflammatory diseases. To stop the replication of the virus, we developed highly potent tetrapeptidic HTLV-I protease inhibitors. In a recent X-ray crystallography study, several of our inhibitors could not form co-crystal complexes with the protease due to their high hydrophobicity. In the current study, we designed, synthesized and evaluated the HTLV-I protease inhibition potency of compounds with hydrophilic end-capping moieties with the aim of improving pharmaceutic and pharmacokinetic properties. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.066
• 作为产物：
  描述：

  乙酸酐 、 1-氨基-2-甲基-2-丙醇 在 吡啶 作用下， 生成 (1-Amino-2-methylpropan-2-yl) acetate
  参考文献：
  名称：

  Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles

  摘要：

  The human T cell leukemia/lymphotropic virus type 1 (HTLV-I) is clinically associated with adult T cell leukemia/lymphoma, HTLV-I associated myelopathy/tropical spastic paraparesis, and a number of other chronic inflammatory diseases. To stop the replication of the virus, we developed highly potent tetrapeptidic HTLV-I protease inhibitors. In a recent X-ray crystallography study, several of our inhibitors could not form co-crystal complexes with the protease due to their high hydrophobicity. In the current study, we designed, synthesized and evaluated the HTLV-I protease inhibition potency of compounds with hydrophilic end-capping moieties with the aim of improving pharmaceutic and pharmacokinetic properties. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.066

文献信息

• METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE
  申请人：Morel Pierre

  公开号：US20080102028A1

  公开（公告）日：2008-05-01

  The present invention relates to new synthetic methods for preparing 2-methoxyisobutylisonitrile and metal isonitrile complexes, such as tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluroroborate, which are used in the preparation of technetium ( 99m Tc) Sestamibi, and novel intermediate compounds useful in such methods.

  本发明涉及新的合成方法，用于制备2-甲氧基异丁基异腈和金属异腈络合物，例如四(2-甲氧基异丁基异腈)铜(I)四氟硼酸盐，这些化合物用于制备锝(99mTc)西斯他米和在此类方法中有用的新型中间体化合物。
• US3935087A
  申请人：——

  公开号：US3935087A

  公开（公告）日：1976-01-27
• US7563920B2
  申请人：——

  公开号：US7563920B2

  公开（公告）日：2009-07-21
• US8703987B2
  申请人：——

  公开号：US8703987B2

  公开（公告）日：2014-04-22
• [EN] ADDITION-FRAGMENTATION AGENTS<br/>[FR] AGENTS D'ADDITION-FRAGMENTATION
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2013028401A1

  公开（公告）日：2013-02-28

  Addition-fragmentation agents of the formula are disclosed having the following functional groups: 1) a labile addition-fragmentation group that can cleave and reform to relieve strain, 2) a free-radically polymerizable group, and 3) a surface-modifying functional group that associates with the surface of a substrate.